Kunal P. Pednekar

Kunal P. Pednekar

Auto-generated profile, based on publicly available information

Kunal P. Pednekar

Engineered Therapeutics Group, Department of Biomaterials Science and Technology, Technical Medical Centre, University of Twente, 7500 AE Enschede, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KPKunal P. Pednekar
Kunal P. Pednekar
MHMarcel Heinrich
Marcel Heinrich
JBJoop van Baarlen
Joop van Baarlen
Jai PrakashJai Prakash
Jai Prakash
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor type with low patient survival due to the low efficacy of current treatment options. Cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME) create a dense fibrotic environment around the tumor cells, preventing therapies from reaching their target. Novel 3D in vitro models are needed that mimic this fibrotic barrier for the development of therapies in a biologically relevant environment. Here, novel PDAC microtissues (µtissues) consisting of pancreatic cancer cell core surrounded by a CAF-laden collagen gel are presented, that is based on the cells own contractility to form a hard-to-penetrate barrier. The contraction of CAFs is demonstrated facilitating the embedding of tumor cells in the center of the µtissue as observed in patients. The µtissues displayed a PDAC-relevant gene expression by comparing their gene profile with transcriptomic patient data. Furthermore, the CAF-dependent proliferation of cancer cells is presented, as well as the suitability of the µtissues to serve as a platform for the screening of CAF-modulating therapies in combination with other (nano)therapies. It is envisioned that these PDAC µtissues can serve as a high-throughput platform for studying cellular interactions in PDAC and for evaluating different treatment strategies in the future.

25 October 2025 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
DMDeby Fajar Mardhian
Deby Fajar Mardhian
KPKunal P. Pednekar
Kunal P. Pednekar
AHAhmed G. Hemdan
Ahmed G. Hemdan
PKPraneeth Reddy Kuninty
Praneeth Reddy Kuninty
SKSaadia A. Karim
Saadia A. Karim
Jai PrakashJai Prakash
Jai Prakash
The tumor–stroma interaction contributes to the aggressive and resistance nature of pancreatic ductal adenocarcinoma (PDAC), leading to treatment failure. Cancer-associated fibroblasts (CAFs), a key cell type in the stroma, produce abundant extracellular matrix (ECM) and exhibit crosstalk with cancer cells inducing chemoresistance. In this study, we designed a cyclic peptide (cyAV3.3) targeting integrin α5 (ITGA5) to disrupt CAF-induced desmoplasia and crosstalk with cancer cells. In vitro, cyAV3.3 inhibited the differentiation of pancreatic stellate cells into CAFs and reduced ECM production. In 3D co-cultured human spheroid models, the peptide decreased markers of resistance (ABCG1, BCL2, CXCR4), stemness (WNT1, CD44) and ECM remodeling (COL1A1, MMP2/9, LOX) and enhanced gemcitabine efficacy. In vivo, radiolabeled cyAV3.3 exhibited high tumor accumulation and retention following parenteral injections in a co-injection xenograft tumor model. Intriguingly, combination of cyAV3.3 with gemcitabine resulted in improved therapeutic efficacy of gemcitabine in co-injection xenograft and genetically engineered LSL-KrasG12D/+LSL-Trp53R172H/+Pdx1-Cre (KPC) PDAC models. These effects were attributed to reduced desmoplasia, vasculature compression and enhanced infiltration of cytotoxic T cells and apoptosis. This study presents a novel cyclic peptide inhibiting ITGA5-mediated tumor–stroma interaction and thereby reduce desmoplasia and resistance, ultimately enhancing chemotherapy efficacy in PDAC.

16 October 2026 in Advanced Healthcare Materials
Verified
Journal Article
Open access
PDF file
KPKunal P. Pednekar
Kunal P. Pednekar
DVDaan Vorselen
Daan Vorselen
Jai PrakashJai Prakash
Jai Prakash
Understanding how stromal and immune cells regulate tumor mechanics is essential for deciphering cancer progression and therapy resistance. This study presents a microparticle‐based traction force microscopy strategy for in situ quantification of compressive forces within 3D tumor spheroids. Multicellular spheroids composed of tumor cells (T), fibroblasts (F), and macrophages (M) were generated to mimic the tumor microenvironment and to understand the contribution of fibroblast–macrophage crosstalk in tumor mechanobiology. Tri‐culture spheroids exhibited the highest proliferative capacity compared to mono‐ and bi‐cultured tumor spheroids. Gene expression profiling indicated strong fibroblast activation, extracellular matrix remodeling, and M2‐like macrophage polarization, highlighting a pro‐tumoral phenotype. Incorporation of deformable hydrogel microparticles allowed direct mapping of local compressive and indirect quantification of anisotropic stresses. This mapping revealed fibroblasts are the principal source of force generation with the spheroids. Notably, macrophages amplified bulk and anisotropic stresses over two‐fold through paracrine activation of fibroblasts. Spatial mapping showed pressure gradients from the core to the periphery, while temporal analyses demonstrated a progressive increase in mechanical stresses with spheroid growth. Together, these findings reveal a surprising governing of intratumoral mechanics by macrophage–fibroblast interactions and demonstrate the potential of microparticle‐based 3D force mapping within complex tumor environments.